Trump’s WHO Exit: Impact on Cancer Research & Funding

The United States is significantly curtailing its engagement with the International Agency for Research on Cancer (IARC), a move that raises concerns about global cancer research and public health initiatives. This decision, stemming from the Trump administration and continuing under the current administration, effectively bars federal scientists from collaborating with IARC and could lead to a substantial reduction in funding for the agency. The shift in policy follows years of criticism leveled at IARC by U.S. Officials regarding its assessments of potential carcinogens, particularly concerning widely used agricultural chemicals.

IARC’s Role and Recent Controversies

IARC, part of the World Health Organization (WHO), is a leading international body dedicated to identifying the causes of cancer. Its evaluations, based on a rigorous review of scientific literature, categorize substances into groups based on their carcinogenic potential – from definitely carcinogenic to possibly carcinogenic. These assessments are crucial for informing public health policies and regulations worldwide. Although, IARC’s findings have frequently drawn scrutiny from industry groups and, increasingly, from U.S. Government officials.

Recent disputes center around IARC’s classifications of substances like glyphosate, a key ingredient in the herbicide Roundup and atrazine, another widely used weedkiller. In March 2026, just a month after the Trump administration doubled down on its support for atrazine, the WHO’s IARC classified it as “probably carcinogenic to humans,” as reported by Common Dreams. This classification has fueled ongoing debate and legal challenges related to the herbicide’s use. Similarly, IARC’s assessment of glyphosate has been a source of contention, with the U.S. Environmental Protection Agency (EPA) consistently reaching different conclusions.

The U.S. Withdrawal and Its Implications

The U.S. Withdrawal, initially initiated during the Trump administration’s broader pullback from the WHO, prevents federal scientists from participating in IARC working groups – the expert panels that conduct the evaluations. This limits U.S. Influence on the agency’s assessments and raises concerns about the objectivity of the process. The policy change could significantly reduce funding for IARC, as the U.S. Has historically been a major contributor. Health Policy Watch details the renewed focus on Trump’s support for ‘elemental phosphorus’ alongside this withdrawal, highlighting a broader pattern of questioning scientific consensus.

The impact extends beyond scientific collaboration and funding. IARC’s evaluations often inform regulatory decisions in other countries, and a diminished U.S. Presence could weaken the agency’s global influence. This could lead to inconsistencies in cancer risk assessments and potentially compromise public health protections internationally.

What Does “Probably Carcinogenic” Mean?

It’s important to understand the terminology IARC uses. “Probably carcinogenic to humans” (Group 2A) means there is limited evidence of carcinogenicity in humans and sufficient evidence in experimental animals. This doesn’t mean the substance *will* cause cancer in everyone exposed, but it indicates a potential risk that warrants further investigation and precautionary measures. The classification is based on the weight of evidence, considering all available scientific data. It’s a nuanced assessment, and often misinterpreted by the public and industry alike.

The Political Context and Industry Influence

The U.S. Government’s stance on IARC is closely linked to the agricultural industry’s concerns about potential restrictions on the use of pesticides and herbicides. The Free Press reports on how the weedkiller debate is “tearing apart Trump’s coalition,” illustrating the political pressures at play. Industry groups have actively lobbied against IARC’s findings, questioning the agency’s methodology and transparency. Critics argue that IARC’s assessments are overly cautious and based on flawed data, while proponents maintain that the agency’s rigorous scientific approach is essential for protecting public health.

The situation highlights the complex interplay between science, politics, and economic interests in shaping public health policy. It also underscores the importance of independent scientific evaluation and the need for transparency in regulatory processes.

Understanding Risk: Absolute vs. Relative

When evaluating the potential risks associated with substances like atrazine or glyphosate, it’s crucial to distinguish between absolute and relative risk. Relative risk compares the risk of cancer in exposed individuals to the risk in unexposed individuals. For example, a relative risk of 2.0 means that exposed individuals are twice as likely to develop cancer as unexposed individuals. However, this doesn’t tell us anything about the overall incidence of cancer. Absolute risk, represents the actual probability of developing cancer in a given population. A small increase in relative risk may translate to a very small increase in absolute risk, particularly if the baseline risk is low.

What Comes Next: Surveillance and Review Processes

The U.S. Withdrawal from IARC does not necessarily mean that the agency’s assessments will be ignored. Other countries and international organizations will continue to rely on IARC’s evaluations, and the agency will continue to conduct its research. The EPA, for example, conducts its own risk assessments of pesticides and herbicides, and these assessments are subject to public comment and scientific review.

Ongoing surveillance of cancer incidence and exposure levels is also critical for monitoring potential risks and informing public health interventions. The National Cancer Institute (NCI) and the Centers for Disease Control and Prevention (CDC) play key roles in this surveillance effort. The scientific community will continue to investigate the potential carcinogenic effects of various substances, and new evidence may emerge that could lead to revisions of existing classifications. The process of evaluating cancer risks is dynamic and iterative, and it requires ongoing vigilance and collaboration.